Skip to main content
. 2020 Oct 20;63(21):12873–12886. doi: 10.1021/acs.jmedchem.0c00774

Figure 1.

Figure 1

Virtual screening of the D3 library of compounds and the experimental test of the most promising hits resulted in the identification of a new type of topoII inhibitor consisting of bicyclic pyrimidines derivatives, which was used to build a structure–activity relationship, from compound 1 (IC50 of 160 μM) to the lead compound 14 (IC50 of 2 μM, ARN-21934).